Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jan;26(1):139-145.
doi: 10.1007/s00520-017-3825-2. Epub 2017 Aug 11.

Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study

Jørn Herrstedt  1 , Yvonne Summers  2 , Gedske Daugaard  3 , Thomas B Christensen  4 , Karin Holmskov  5 , Paul D Taylor  2 , Gabriel M Fox  6 , Alexander Molassiotis  7   8
Affiliations
Clinical Trial

Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study

Jørn Herrstedt et al. Support Care Cancer. 2018 Jan.

Abstract

Purpose: The purpose of this study was to investigate the antiemetic effect of the dopamine D2- and dopamine D3-receptor antagonist, amisulpride, in patients receiving cisplatin-based chemotherapy.

Methods: This dose-finding, non-comparative study investigated the antiemetic effect and safety of increasing doses (2.5, 7.5 and 20 mg) of amisulpride against acute nausea and vomiting in the period 0-24 h after initiation of cisplatin-based chemotherapy. The 20 mg dose was also investigated in combination with the 5-HT3-receptor antagonist, ondansetron. The primary parameter was complete response (0-24 h), defined as no emesis and no need for rescue antiemetics. Secondary parameters were number of emetic episodes, severity of nausea and time to first emetic episode and start of nausea.

Results: A total of 51 patients were enrolled and evaluable. None of the 10 patients in the 2.5 and 7.5 mg groups obtained a CR. In the 20 mg monotherapy cohort, two of the 18 subjects (11%) had a CR, 3/18 (17%) had no emesis and 12/18 (67%) had no significant nausea. Seven subjects (39%) had no nausea at all (a VAS score < 5 mm). In the combination (ondansetron plus amisulpride) cohort, 19/23 (83%; 90% confidence interval: 65-94%) had a CR and 14/23 (61%) had no nausea at all.

Conclusions: Amisulpride has antiemetic effect against cisplatin-induced acute nausea and vomiting. The effect against nausea is of particular interest. Randomised studies are warranted to further explore the effect and safety of amisulpride.

Keywords: Amisulpride; Chemotherapy; Cisplatin; Dopamine antagonist; Nausea; Vomiting.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Dan Med Bull. 1998 Sep;45(4):412-22 - PubMed
    1. Br J Clin Pharmacol. 2017 Feb;83(2):339-348 - PubMed
    1. Ann Oncol. 2014 Jul;25(7):1340-6 - PubMed
    1. Br J Anaesth. 2013 Dec;111(6):938-45 - PubMed
    1. J Clin Oncol. 1991 Apr;9(4):675-8 - PubMed

Publication types

MeSH terms

LinkOut - more resources